Management of Endometrial Cancer

Mirza, Mansoor R.

  • 出版商: Springer
  • 出版日期: 2019-10-20
  • 售價: $4,870
  • 貴賓價: 9.5$4,627
  • 語言: 英文
  • 裝訂: Hardcover - also called cloth, retail trade, or trade
  • ISBN: 3319645129
  • ISBN-13: 9783319645124
  • 下單後立即進貨 (約3~6週)

相關主題

商品描述

This practical reference book provides up-to-date, evidence-based multidisciplinary guidelines on the epidemiology, biology, diagnosis, and treatment of endometrial cancer. Individual chapters focus on topics such as hormonal interactions, cancer prevention, genetic classification and its clinical applications. Recent advances in diagnostic methods are described. The treatment-oriented chapters include coverage of the roles of lymphadenectomy and sentinel node dissection, surgical complications, radiation techniques, and chemotherapy in early-stage disease. Treatment options in advanced disease, including hormonal therapy and targeted therapy, are considered separately, as is the management of rare tumor types. The authors are international key opinion leaders. Summaries of the ESMO/ESGO/ESTRO guidelines on management are included. Each clinical chapter ends with a summary of recommendations with the level of evidence.

作者簡介

Mansoor R. Mirza is medical & radiation oncologist, involved in the management of gynaecologic cancers. He is Chief Oncologist at Rigshospitalet, Copenhagen and Medical Director of Nordic Society of Gynaecological Oncology (NSGO). His key academic goals are to promote clinical research, international trial collaboration and education. He is author and principle investigator of several phase I, II and III studies. He is chair/member of Independent Data Monitoring Committee (IDMC) of several international trials. He is co-author of ESMO-ESGO-ESTRO consensus guidelines on endometrial and vulvar cancers, senior author of national guidelines for endometrial cancer, cervical cancer, vulvar cancer and non-epithelial ovarian cancer as well as of NSGO radiotherapy guidelines. He serves in Board of Directors of Gynecologic Cancer Inter Group (GCIG) and faculty of European Society of Medical Oncology (ESMO). He also serves in Board of Directors of biotech companies like, Karyopharm

Therapeutics Inc., Metamark Genetics Inc. and Sera Prognostics Inc. He has multiple publications and book chapters and serves in editorial board or is reviewer of several journals.